Drug Induced Liver Injury (DILI)
|
|
- Maude Dean
- 5 years ago
- Views:
Transcription
1 Drug Induced Liver Injury (DILI) Aisling Considine- Consultant Hepatology Pharmacist. King s College Hospital NHS Foundation Trust aislingconsidine@nhs.net
2 Drug Induced Liver Injury /Disease Acute Liver Failure N Engl J Med 2013;369:
3 Type of Drug Reactions Intrinsic Predictable Dose Dependent Tend to occur rapidly e.g. within hours Tend to cause necrosis, acute Liver failure e.g. Paracetamol overdose Idiosyncratic Not predictable Not dose dependent Tend to take longer to occur weeks to months Can result from metabolic idiosyncrasy or immunoallergic reaction Can cause any type of Liver injury e.g. increased LFTs, jaundice, fever, rash E.g. NSAIDS (metabolic), Carbamazepine
4 Drug Induced Liver Disease Risk factors which may pre-dispose to DILD: Gender (tends to be more common in females) Age Genetics Concurrent diseases e.g. obesity, diabetes, co-infection with HIV Polypharmacy
5 Is it a Drug Induced Liver Injury? Expert judgement 1. Is there a relationship between symptoms & drug 2. Are there pre existing reports of DILI with drug 3. Did symptoms initially improve on stopping drug Probabilistic approaches Algorithms or scales No gold standard Council for International Organizations of Medical Sciences (CIOMS) scale, also referred to as the Roussel Uclaf Causality Assessment Method (RUCAM) The scale applies numerical weighting to key features in seven different domains: 1. chronology,risk factors, concomitant 2. drug use, search for other aetiologies, 3. existing information on the drug s hepatotoxic potential, 4. response to rechallenge In cases of acute or severe fulminant hepatitis -liver biopsy Journal of Hepatology 2011 vol. 55 j
6 DILD Acute Liver Failure (ALF) ALF is a syndrome defined by a rapid decline in hepatic function characterized by; 1. jaundice 2. coagulopathy (INR >1.5) 3. hepatic encephalopathy in patients with no evidence of prior liver disease Management will depend on specific case DILI is traditionally defined as an; 1. increase in alanine aminotransferase (ALT) 5 times ULN; 2. alkaline phosphatase (ALP) 2 times ULN or a; 3. combination of ALT 3 times ULN and bilirubin 2 times above the ULN Clin Liver Dis 21 (2017) 35 54
7 Case 1 herbal remedy Patient -60yr old Caucasian female PmHx -Migraine, Hypothyroidism Meds on Admission Propranolol 20mg od Levothyroxine 100mcg od Black Cohosh (Traubensilberkerze) 2 tabs bd ( 4 weeks of treatment now stopped) No allergies Presenting Complaint General Practitioner review pruritus and dark urine Of Note No risk factors for viral hepatitis No family history No alcohol
8 Black Cohosh (Traubensilberkerze) Derived from a plant of the buttercup family Claims to have estrogen-like effects Used for relief of symptoms of menopause Linked to > fifty instances of clinically apparent liver injury including death Clinical presentation -typically with jaundice and with liver biopsy histology resembling acute viral hepatitis
9 Potential Hepatotoxic Herbal Remedies A helpful resource that is available to clinicians trying to ascertain whether a drug or supplement may be hepatotoxic
10 Bloods Case 1
11 Imaging Case 1 Patients abdominal CT
12 Diagnosis Acute liver failure secondary to DILI (black cohosh) Plan: Liver Transplantation
13 Management Case 1 STOP THE DRUG IN QUESTION i.e. Black Cohosh Infection Antimicrobials broad spectrum Renal replacement (hyperammonia and lactic acidosis) Filtration Glucose Control Dextrose 30% continuous infusion Pressure Control & Cardiac Output Fluids and pressors (noradrenaline & vasopressin) Antioxidant N-acetylcysteine
14 Liver Transplantation Immunosuppression Tacrolimus, Mycophenolate, Azathioprine, Ciclosporin, steroids Antimicrobials Broad Spectrum Analgesia Paracetamol and opiates when required
15 ,5 3 2,5 2 1, Bilirubin umol/l AST IU/L 1 0,5 INR 0 0
16 Case 2 Paracetamol Overdose Patient -27 year old male PmHx - Depression (severe), excess alcohol (40-50 units/week ~ 5 bottles/week of "Schwäbischen Wein ), smoker, cannabis, cocaine use Meds on Admission Nil regular No allergies No herbal remedies Presenting Complaint Staggered paracetamol overdose over 2 days Took 48 x 500mg tablets paracetamol and 32 x 200mg ibuprofen Presented to A&E vomiting and lactic acidosis High ammonia Of Note No risk factors for viral hepatitis No family history Action Transferred to intensive care Br J Clin Pharmacol / 73:2 / / 285
17 * About 5 15% of a dose of paracetamol is hepatically metabolized to a highly reactive hepatotoxic metabolite.the half-life of paracetamol can be nearly doubled in hepatic impairment. Still used in severe hepatic impairment with appropriate caution *
18
19 Diagnosis and Action ALF secondary to paracetamol and ibuprofen induced liver injury Acute renal failure likely corticol necrosis due to ibuprofen Background evaluation Anxiety managed by GP, no previous deliberate self harm Overdose secondary to relationship breakdown Alcohol excess Action 28/7/17 listed for liver transplant 1/8/17 delisted due to no longer fulfilling national criteria Managed as per case 1 anti-microbials, filtration, pressors,nacetylcysteine
20 Bloods Case 2
21
22 Recovery Case 2 Spent 4 weeks on intensive care Stepped down to ward Irreversible damage to kidneys dialysis dependent (DILI not always reversible) Liver recovery to baseline Ongoing severe depression
23 Case 3 Dimethyl Fumarate Patient -43yr old Caucasian female PmHx Multiple sclerosis Meds on Admission Dimethyl Fumarate - started 12 weeks prior to admission Paracetamol when required No allergies Presenting Complaint Admitted to hospital with confusion and jaundice Of Note No risk factors for viral hepatitis No family history No alcohol
24 Product Characteristics Drug-induced liver injury, including liver enzyme increase ( 3 ULN) and elevation of total bilirubin levels ( 2 ULN) can result from treatment with Tecfidera. The time to onset can be directly, several weeks or longer. Resolution of the adverse events has been observed after treatment was discontinued. Assessment of serum aminotransferases (e.g. ALT, AST) and total bilirubin levels are recommended prior to treatment initiation and during treatment as clinically indicated. accessed 28/4/17
25 Diagnosis Acute Liver failure secondary to DILI secondary to Dimethyl Fumarate Date Biochemistry Result Range On presentation Day 1 Bilirubin 320umol/L 5-20 Alanine Transaminase Aspartate Transaminase INR /PT Ammonia IU/L /22.6seconds 140umol/L Viral Screen Hepatitis A,B,C,E negative EBV,CMV,Autoantibodies negative Imaging CT scan Shrunken liver, no malignancy Paracetamol Level negative
26 Imaging
27 Patient died Clinical Course Patient fulfilled listing criteria for urgent liver transplant and was treated as per case 1 & 2 Day 4 on intensive care blood pressure dropped not responding to increased support Sepsis pseudomonas on BAL Worsening lactic acidosis By day 6 thought to be too unwell to undergo liver transplantation Broad-spectrum antibiotic therapy was changed However, she continued to deteriorate and ultimately displayed rapid decline in her cardiac and metabolic status
28 Bloods Case 3 All patients with liver disease will have raised transaminase enzymes? True /False
29 Bloods Case 3
30
31 Summary DILI &Usefulness of LFTs to Guide Prescribing Drug metabolism very complex and not fully understood. Albumin, INR, PT and Bilirubin are considered the best predictors (synthetic and excretory function) Liver will carry out drug metabolism even in cirrhotic patients Difficult to predict PK changes in individual patients Consider route elimination renal, biliary etc Limited studies in the area of DILI dependant on reports In theory any drug has the potential to cause a DILI Patient specific background, environmental factors etc.
1. Based on A.S. s labs and presentation, what type of liver injury would you classify her as experiencing?
Drug Induced Liver Injury Cases Case #1 A.S., a16 year-old female, was found by her pediatrician to be slightly jaundiced during a routine school physical. She denied any history of liver disease, abdominal
More informationABNORMAL LIVER FUNCTION TESTS. Dr Uthayanan Chelvaratnam Hepatology Consultant North Bristol NHS Trust
ABNORMAL LIVER FUNCTION TESTS Dr Uthayanan Chelvaratnam Hepatology Consultant North Bristol NHS Trust INTRODUCTION Liver function tests Cases Non invasive fibrosis measurement Questions UK MORTALITY RATE
More informationAbnormal Liver Chemistries. Lauren Myers, MMsc. PA-C Oregon Health and Science University
Abnormal Liver Chemistries Lauren Myers, MMsc. PA-C Oregon Health and Science University Disclosure 1. The speaker/planner Lauren Myers, MMSc, PA-C have no relevant financial relationships to disclose
More informationDrug-induced liver injury
Drug-induced liver injury Vincent Wong MBChB(Hons), MD, FRCP, FHKCP, FHKAM Professor, Department of Medicine and Therapeutics Director, Cheng Suen Man Shook Foundation Centre for Hepatitis Studies Deputy
More informationKing s College Hospital NHS Foundation Trust. Acute Liver Disease: what you really need to know.
King s College Hospital NHS Foundation Trust Acute Liver Disease: what you really need to know. William Bernal Professor of Liver Critical Care Liver Intensive Therapy Unit Institute of Liver Studies Kings
More informationChapter 143 Acetaminophen
Chapter 143 Acetaminophen Episode overview 1) Describe the metabolism of Acetaminophen 2) Describe the 4 stages of Acetaminophen toxicity 3) List 4 mechanism of action of N-acetylcysteine 4) When do you
More informationDR J HARTY / DR CM RITCHIE / DR M GIBBONS
CLINICAL GUIDELINES ID TAG Title: Author: Speciality / Division: Directorate: Paracetamol Poisoning DR J HARTY / DR CM RITCHIE / DR M GIBBONS Medicine Acute Date Uploaded: 16 th September 2014 Review Date
More informationDiagnostic evaluation of suspected Drug-Induced Liver Injury
Diagnostic evaluation of suspected Drug-Induced Liver Injury Ynto de Boer, MD Department of Gastroenterology and Hepatology Disclosure No disclosures Drug-induced liver injury? Outline What is DILI? What,
More informationMATRIX (Methotrexate, Cytarabine, Thiotepa and Rituximab)
MATRIX (Methotrexate, Cytarabine, Thiotepa and Rituximab) Indication First line treatment of primary CNS lymphoma. ICD-10 codes Codes with a prefix C85 Regimen details Day Drug Dose Route 1 and 6 Rituximab
More informationMANAGEMENT OF DILI in TB/HIV coinfected patients. Chimoio 31 August 2017 by Dr Ndiviwe Mphothulo
MANAGEMENT OF DILI in TB/HIV coinfected patients Chimoio 31 August 2017 by Dr Ndiviwe Mphothulo ANTI-TB drugs Groups Drugs Group 1: First-line oral drugs Ethambutol (Emb) Pyrazinamide(PZA) Isoniazid (INH)
More informationPatterns of abnormal LFTs and their differential diagnosis
Patterns of abnormal LFTs and their differential diagnosis Professor Matthew Cramp South West Liver Unit and Peninsula Schools of Medicine and Dentistry, Plymouth Outline liver function tests / tests of
More informationVIRAL HEPATITIS. Definitions. Acute Liver Disease (Hepatitis A &E, Alcoholic hepatitis, DILI and ALF) Acute Viral Hepatitis Symptoms
Acute Liver Disease (Hepatitis A &E, Alcoholic hepatitis, DILI and ALF) Definitions AST and ALT Markers of hepatocellular injury Ryan M. Ford, MD Assistant Professor of Medicine Director of Viral Hepatitis
More informationThe predictive value of serum alanine transaminase activity on first presentation to hospital in patients with paracetamol poisoning
The predictive value of serum alanine transaminase activity on first presentation to hospital in patients with paracetamol poisoning Khalid Al-Hourani, Rachel Mansi, Janice Pettie, Margaret Dow, Nick Bateman
More informationIpilimumab (skin) Indication Advanced (unresectable or metastatic) melanoma in patients who have received prior therapy.
Ipilimumab (skin) Indication Advanced (unresectable or metastatic) melanoma in patients who have received prior therapy. (NICE TA268) ICD-10 codes Codes prefixed with C43 Regimen details Day Drug Dose
More informationTB Case Management Hepatitis
TB Case Management Hepatitis Chris Keh, MD TB Controller, TB Prevention and Control Program, San Francisco Department of Public Health Assistant Clinical Professor, Division of Infectious Diseases, University
More informationCITY AND HACKNEY CCG ABNORMAL LIVER FUNCTION TESTS (LFTs) in ADULTS
CITY AND HACKNEY CCG ABNORMAL LIVER FUNCTION TESTS (LFTs) in ADULTS Interpreting abnormal liver function tests (LFTs) and trying to diagnose any underlying liver disease is a common scenario in Primary
More informationInvestigating and Referring Incidental Findings of Abnormal Liver Tests
Investigating and Referring Incidental Findings of Abnormal Liver Tests Note on Referral Guidelines: these revised guidelines are presented as a tool to aid appropriate referral and management of common
More informationLeonard B. Seeff, M.D. Consultant Einstein Healthcare Network. Click to view Biosketch and Presentation Abstract or page down to review presentation
Leonard B. Seeff, M.D. Consultant Einstein Healthcare Network Click to view Biosketch and Presentation Abstract or page down to review presentation ALT as a Biomarker for Drug-Induced Liver Injury Leonard
More informationNivolumab and Ipilimumab
Nivolumab and Ipilimumab Indication Advanced (unresectable or metastatic) melanoma. (NICE TA400) ICD-10 codes Codes prefixed with C43 Regimen details Cycles 1-4 Nivolumab and Ipilimumab every 3 weeks Day
More informationPACT module Acute hepatic failure. Intensive Care Training Program Radboud University Medical Centre Nijmegen
PACT module Acute hepatic failure Intensive Care Training Program Radboud University Medical Centre Nijmegen Acute Liver Failure Acute on Chronic Liver Failure Acute loss of hepatocellular function in
More informationPACT module Acute hepatic failure. Intensive Care Training Program Radboud University Medical Centre Nijmegen
PACT module Acute hepatic failure Intensive Care Training Program Radboud University Medical Centre Nijmegen Acute Liver Failure Acute on Chronic Liver Failure Acute loss of hepatocellular function in
More informationHIV/AIDS and the Liver : interlinking challenges
HIV/AIDS and the Liver : interlinking challenges Mark W. Sonderup Division of Hepatology Department of Medicine University of Cape Town & Groote Schuur Hospital Global HIV/AIDS prevalence 37 million people
More informationWEEK. MPharm Programme. Liver Biochemistry. Slide 1 of 49 MPHM14 Liver Biochemistry
MPharm Programme Liver Biochemistry Slide 1 of 49 MPHM Liver Biochemistry Learning Outcomes Assess and evaluate the signs and symptoms of illness Assess and critically appraise a patients medication regimen,
More informationEVALUATION OF ABNORMAL LIVER TESTS
EVALUATION OF ABNORMAL LIVER TESTS MIA MANABAT DO PGY6 MOA 119 TH ANNUAL SPRING SCIENTIFIC CONVENTION MAY 19, 2018 EVALUATION OF ABNORMAL LIVER TESTS Review of liver enzymes vs liver function tests Clinical
More informationIpilimumab in Melanoma
Ipilimumab in Melanoma Indication: Advanced (unresectable or metastatic) melanoma in adults who have received prior therapy LCNDG criteria to be met: Histologically confirmed unresectable stage III or
More informationChronic Hepatic Disease
Chronic Hepatic Disease 10 th Leading Cause of Death Liver Functions Energy Metabolism Protein Synthesis Solubilization, Transport, and Storage Protects and Clears drugs, damaged cells Causes of Liver
More informationTreatment monitoring protocol for Dimethyl fumarate therapy in active Relapsing Remitting Multiple Sclerosis
Treatment monitoring protocol for Dimethyl fumarate therapy in active Relapsing Remitting Multiple Sclerosis This protocol provides monitoring guidance for adult patients requiring Dimethyl fumarate therapy
More informationLiver failure &portal hypertension
Liver failure &portal hypertension Objectives: by the end of this lecture each student should be able to : Diagnose liver failure (acute or chronic) List the causes of acute liver failure Diagnose and
More informationAmbulatory Emergency Care Pathways. Painless Obstructive Jaundice
Ambulatory Emergency Care Pathways Painless Obstructive Jaundice Effective Date: December 2011 Content Summary Ref Title Description 1 Condition Details Identifies pathway details and clinical sign-off
More informationAtezolizumab Non-small cell lung cancer
Systemic Anti Cancer Treatment Protocol Atezolizumab Non-small cell lung cancer PROTOCOL REF: MPHAATNSCLC (Version No: 1.0) Approved for use in: Locally advanced/metastatic non squamous or squamous non-small
More informationSuspected Isoflurane Induced Hepatitis from Cross Sensitivity in a Post Transplant for Fulminant Hepatitis from Halothane.
ISPUB.COM The Internet Journal of Anesthesiology Volume 25 Number 1 Suspected Isoflurane Induced Hepatitis from Cross Sensitivity in a Post Transplant for Fulminant Hepatitis from Halothane. V Sampathi,
More informationR-IDARAM. Dexamethasone is administered as an IV infusion in 100mL sodium chloride 0.9% over 30 minutes.
R-IDARAM Indication Secondary CNS lymphoma ICD-10 codes Codes with a prefix C85 Regimen details Day Drug Dose Route 1 Rituximab 375mg/m 2 IV infusion 1 Methotrexate 12.5mg Intrathecal 1 Cytarabine 70mg
More informationManagement of Patients with Past or Present Hepatic Abnormalities
S21 Management of Patients with Past or Present Hepatic Abnormalities Evidence Based Medicine Official recommendations Expert opinion Course of action before tocilizumab therapy in patients with a history
More informationCurrent Concepts in Diagnosis and Management of Acute Liver Failure
Current Concepts in Diagnosis and Management of Acute Liver Failure Oren Fix, MD, MSc, FACP, AGAF, FAASLD Medical Director, Liver Transplant Program Swedish Medical Center Seattle, WA Learning Objectives
More informationHepatology cases for the generalist. Will Gelson Consultant Hepatologist Addenbrooke s Hospital
Hepatology cases for the generalist Will Gelson Consultant Hepatologist Addenbrooke s Hospital 30 y o man with upper GI haemorrhage Background heavy alcohol use Hxof 3 pint haematemesis P 100, BP 90/40,
More informationDimethyl Fumarate (Tecfidera) pathway for Walton Centre MS patients
Dimethyl Fumarate (Tecfidera) pathway for Walton Centre MS patients Author and Contact details: Responsible Director: Ian Pomeroy Service lead for MS. Tel: (0151) 529 5715 Email: ian.pomeroy@thewaltoncentre.nhs.uk
More informationWhat to do with abnormal LFTs? Andrew M Smith Hepatobiliary Surgeon
What to do with abnormal LFTs? Andrew M Smith Hepatobiliary Surgeon "it looks like there's something wrong.with your television set. Matt Groenig, creator of The Simpsons Probability of an abnormal screening
More informationPatterns of abnormal LFTs and their differential diagnosis
Patterns of abnormal LFTs and their differential diagnosis Professor Matthew Cramp South West Liver Unit and Peninsula Schools of Medicine and Dentistry, Plymouth Outline liver function / liver function
More informationCisplatin / Paclitaxel Gynaecological Cancer
Systemic Anti Cancer Treatment Protocol Cisplatin / Paclitaxel Gynaecological Cancer PROCTOCOL REF: MPHAGYNCIP (Version No: 1.0) Approved for use in: First line treatment for stage Ib-IV with minimal residual
More informationCrackCast Episode 28 Jaundice
CrackCast Episode 28 Jaundice Episode overview: 1) Describe heme metabolism 2) List common pre-hepatic/hepatic/post-hepatic causes of jaundice Wisecracks: 1) What are clinical signs of liver disease? 2)
More informationSupplementary Online Content
Supplementary Online Content Powles T, O Donnell PH, Massard C, et al. Efficacy and safety of durvalumab in locally advanced or metastatic urothelial carcinoma: updated results from a phase 1/2 openlabel
More informationM0BCore Safety Profile
M0BCore Safety Profile Active substance: Aciclovir Pharmaceutical form(s)/strength: Tablets 200, 400 or 800 mg Dispersible tablets 200, 400 or 800 mg Oral suspensions 200 mg or 400 mg per 5 ml. Freeze
More informationFarmadol. Paracetamol 10 mg/ml INFUSION SOLUTION
Farmadol Paracetamol 10 mg/ml INFUSION SOLUTION Composition Each ml contains: Paracetamol 10 mg Pharmacology Pharmacodynamic properties The precise mechanism of the analgesic and antipyretic properties
More informationNCCP Chemotherapy Regimen. Alectinib Monotherapy
INDICATIONS FOR USE: Alectinib INDICATION ICD10 Regimen Code *Reimbursement Indicator Treatment of adult patients with anaplastic lymphoma kinase (ALK)- positive advanced non-small cell lung cancer (NSCLC)
More informationEvaluation of prognostic markers in severe drug-induced liver disease
PO Box 2345, Beijing 100023, China World J Gastroenterol 2007 January 28; 13(4): 628-632 World Journal of Gastroenterology ISSN 1007-9327 wjg@wjgnet.com 2007 The WJG Press. All rights reserved. RAPID COMMUNICATION
More informationTopic review - A patient with impaired liver function. Dr. Karen Hin Kwan Luk 18/1/2018
Topic review - A patient with impaired liver function Dr. Karen Hin Kwan Luk 18/1/2018 Case M/69 PMH: 1. Diabetes 2. Hypertension 3. Hyperlipidaemia 4. Paroxysmal supraventricular tachycardia 5. Cerebral
More informationThey are a cure, yes. The good news is that a lot of what I was going to talk about has been covered very nicely this morning. So, I think what I am
They are a cure, yes. The good news is that a lot of what I was going to talk about has been covered very nicely this morning. So, I think what I am going to try to do is give you some examples of some
More informationProducts available Methotrexate tablets 2.5mg ONLY (Methotrexate tablets 10mg are NOT recommended as per NPSA guidance 5 ).
Methotrexate Traffic light classification- Amber 1 Information sheet for Primary Care Prescribers Part of the Shared Care Protocol: Management of Rheumatological Conditions with Disease-Modifying Anti
More information2. Liver blood tests and what they mean p2 Acute and chronic liver screen
Hepatology referral pathways for GP 1 Scope For use within hepatology Contents 2. Liver blood tests and what they mean p2 Acute and chronic liver screen p2 Common reasons for hepatology referral 3. Raised
More informationACG Clinical Guideline: Evaluation of Abnormal Liver Chemistries
ACG Clinical Guideline: Evaluation of Abnormal Liver Chemistries Ashwani K. Singal, MD, MS, FACG 1, Ramon Bataller, MD, PhD, FACG 2, Joseph Ahn, MD, MS, FACG (GRADE Methodologist) 3, Patrick S. Kamath,
More informationDrug Induced Liver Disease Role of the Pathologist. Disclosure. DILI can never be excluded. Romil Saxena, MD. Dr. Saxena has nothing to Disclose
Drug Induced Liver Disease Role of the Pathologist Romil Saxena, MD Disclosure Dr. Saxena has nothing to Disclose DILI can never be excluded #1 DILI has no specific pattern of injury it can mimic any and
More informationJINARC (tolvaptan) Healthcare professional educational guide
JINARC (tolvaptan) Healthcare professional educational guide Contents Abbreviations 3 What is the purpose of this brochure? 4 What is JINARC? What is JINARC indicated for? When should treatment not be
More informationCisplatin and Gemcitabine (bladder)
Cisplatin and Gemcitabine (bladder) Indication Palliative therapy for locally advanced or metastatic bladder cancer in patients with good renal function. Palliative therapy for urothelial transitional
More informationExample Clinician Educational Material for Providers of Immune Effector Cellular Therapy
Example Clinician Educational Material for Providers of Immune Effector Cellular Therapy Disclaimer: This example is just one of many potential examples of clinician education material that can be provided
More informationSalicylates commonly cause tinnitus, deafness, nausea and vomiting (salicylism). Hyperventilation results from stimulation of respiratory centre.
Aspirin poisoning CLINICAL FEATURES Salicylates commonly cause tinnitus, deafness, nausea and vomiting (salicylism). Hyperventilation results from stimulation of respiratory centre. Severe poisoning causes
More informationOrkambi. Orkambi (lumacaftor/ivacaftor) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.45.06 Subject: Orkambi Page: 1 of 6 Last Review Date: November 30, 2018 Orkambi Description Orkambi (lumacaftor/ivacaftor)
More informationMDR TB/HIV INTEGRATION MDR TB WORKSHOP 18 SEPTEMBER 2015
MDR TB/HIV INTEGRATION MDR TB WORKSHOP 18 SEPTEMBER 2015 HIV & MDR :Impact of early ART initiation Adjusted HR: 0.14; p = 0.042 86% reduction in mortality with ART Initiation during MDR-TB treatment 2015
More informationLIVER DISORDERS (PRACTICAL MANAGEMENT) Dr Pok Kern (PK) TAN Gastroenterologist Calvary hospital, ACT 1 st April 2017
LIVER DISORDERS (PRACTICAL MANAGEMENT) Dr Pok Kern (PK) TAN Gastroenterologist Calvary hospital, ACT 1 st April 2017 TOPICS TO COVER Acute liver failure Chronic liver failure Portal hypertension : Ascites
More informationPrescribing Framework for Methotrexate for Immunosuppression in ADULTS
Hull & East Riding Prescribing Committee Prescribing Framework for Methotrexate for Immunosuppression in ADULTS Patient s Name:.. NHS Number: Patient s Address:... (Use addressograph sticker) GP s Name:...
More informationChronic Liver Disease after Acute Hepatocellular DILI
Chronic Liver Disease after Acute Hepatocellular DILI Robert J. Fontana, MD University of Michigan Medical Center DILI Natural history of acute DILI Transplant/ death Chronic DILI Chronic DILI Incidence
More informationNovel Therapies in Autoimmune Hepatitis
Novel Therapies in Autoimmune Hepatitis Paul W. Rassam,MD Ass. Clinical Professor of Medicine Div. of Gastroenterology and Hepatology St George Hospital University Medical Center University of Balamand
More informationInformation leaflet for primary care: Agomelatine
Information leaflet for primary care: Agomelatine Background information Agomelatine is an antidepressant indicated for the treatment of major depressive episodes in adults. Agomelatine is a melatonin
More informationAutoimmune Hepatobiliary Diseases PROF. DR. SABEHA ALBAYATI CABM,FRCP
Autoimmune Hepatobiliary Diseases PROF. DR. SABEHA ALBAYATI CABM,FRCP Autoimmune hepatobiliary diseases The liver is an important target for immunemediated injury. Three disease phenotypes are recognized:
More informationPBC/AIH variant/ overlap syndrome vs PBC with hepatitic features?
22 November 2018 BD-IAP UK-LPG Liver Update PBC/AIH variant/ overlap syndrome vs PBC with hepatitic features? in a UDCA non-responder Dina G. Tiniakos Institute of Cellular Medicine, Faculty of Medical
More informationCarboplatin and Fluorouracil
Carboplatin and Fluorouracil Indication Palliative chemotherapy for recurrent or metastatic head and neck squamous cell cancer for patients where cisplatin and / or cetuximab are not appropriate. Performance
More informationDANTROLENE SODIUM IS a muscle relaxant that acts
ORIGINAL ARTICLE Safety of Low-Dose Oral Dantrolene Sodium on Hepatic Function Jung Yoon Kim, MD, Sewoong Chun, MD, Moon Suk Bang, MD, PhD, Hyung-Ik Shin, MD, PhD, Shi-Uk Lee, MD, PhD ABSTRACT. Kim JY,
More informationTB Grand Rounds. Reynard McDonald, MD & Henry Fraimow, MD January 30, Outline
TB Grand Rounds Reynard McDonald, MD & Henry Fraimow, MD January 30, 2007 Outline Overview of 2006 ATS statement regarding hepatotoxicity of anti-tb therapy Case examples highlighting management of patients
More informationATEZOLIZUMAB (TECENTRIQ ) in urothelial carcinoma
DRUG ADMINISTRATION SCHEDULE Day Drug Daily Dose Route Diluent Rate Day 1 Atezolizumab 1200 mg IV Infusion 250mL 0.9% Sodium Chloride Over 60 minutes* *The initial dose of atezolizumab must be administered
More informationMrs Janet Catt. Pre-Conference Nurse s Course. Royal Free London NHS Foundation Trust. Janet Catt MSc RN Lead Nurse Specialist Practic 12/12/2014
Pre-Conference Nurse s Course in partnership with Mrs Janet Catt Royal Free London NHS Foundation Trust Janet Catt MSc RN Lead Nurse Specialist Practic 1 Liver blood tests monitoring cirrhosis HIV/HCV
More informationLapatinib and Capecitabine Therapy
Lapatinib and Capecitabine Therapy This protocol should be read in conjunction with NCCP protocol 00216 Capecitabine Monotherapy. INDICATIONS FOR USE: INDICATION Treatment of adult patients with breast
More informationHHS Public Access Author manuscript Hepatology. Author manuscript; available in PMC 2017 March 01.
Febuxostat-Induced Acute Liver Injury Matt Bohm, DO, Raj Vuppalanchi, MD, Naga Chalasani, MD, and Drug Induced Liver Injury Network (DILIN) Department of Medicine, Indiana University School of Medicine,
More informationManagement of Acute HCV Infection
Management of Acute HCV Infection This section provides guidance on the diagnosis and medical management of acute HCV infection, which is defined as presenting within 6 months of the exposure. During this
More informationYONDELIS (trabectedin) DOSING & ADMINISTRATION GUIDE
YONDELIS (trabectedin) DOSING & ADMINISTRATION GUIDE INDICATION YONDELIS (trabectedin) is indicated for the treatment of patients with unresectable or metastatic liposarcoma or leiomyosarcoma who received
More informationSAFETY CONSIDERATIONS WITH YONDELIS (trabectedin)
SAFETY CONSIDERATIONS WITH YONDELIS (trabectedin) Please see Important Safety Information on pages 14 and 15 and accompanying full Prescribing Information. YONDELIS (trabectedin) STUDY DESIGN INDICATION
More informationCisplatin and Fluorouracil (palliative)
Cisplatin and Fluorouracil (palliative) Indication Palliative chemotherapy for recurrent or metastatic head and neck squamous cell cancer where combination treatment with cetuximab is not indicated. PS0-1
More informationDosage and Administration
SIRTURO product information for healthcare providers 2 WARNINGS: An increased risk of death was seen in the SIRTURO (bedaquiline) treatment group (9/79, 11.4%) compared to the placebo treatment group (2/81,
More informationPatient Group Direction for the Supply of Nitrofurantoin MR 100mg capsules
October 2016 Patient Group Direction for the Supply of Nitrofurantoin MR 100mg capsules This Patient Group Direction (PGD) is a specific written instruction for the supply and/or administration of nitrofurantoin
More informationDrug Induced Liver Injury Associated with Daptomycin: A Case Report and Cohort
AAC Accepts, published online ahead of print on 12 May 2014 Antimicrob. Agents Chemother. doi:10.1128/aac.03157-14 Copyright 2014, American Society for Microbiology. All Rights Reserved. 1 2 Drug Induced
More informationChronic Hepatitis. Andrew Bathgate Chris Bellamy Royal Infirmary of Edinburgh
Chronic Hepatitis Andrew Bathgate Chris Bellamy Royal Infirmary of Edinburgh Autoimmune Hepatitis Annual incidence 1.9/100 000 in N Europe Prevalence 16.9/100 000 ~5% all liver transplants Female preponderance
More informationDurvalumab (previously known as MEDI 4736) Maintenance (Arm A3) PLATFORM study
Durvalumab (previously known as MEDI 4736) Maintenance (Arm A3) PLATFORM study PLAnning Treatment For Oesophago-gastric cancer: a Randomised Maintenance therapy trial. ***See Protocol for further details***
More informationIxazomib with Lenalidomide and Dexamethasone (IRd)
Indication Ixazomib, with lenalidomide and dexamethasone, is recommended for use within the Cancer Drugs Fund as an option for treating multiple myeloma for patients who have already had 2 or 3 lines of
More informationAcute Kidney Injury. Patient Information Leaflet
Acute Kidney Injury Patient Information Leaflet What is Acute Kidney Injury (AKI)? Acute Kidney injury is a rapid fall in kidney function in a person who has become unwell. It can happen over hours or
More informationTIP Paclitaxel, Ifosfamide and Cisplatin
Systemic Anti Cancer Treatment Protocol TIP Paclitaxel, Ifosfamide and Cisplatin PROTOCOL REF: MPHATIPGC (Version No: 1.0) Approved for use in: Second line treatment of germ cell tumours Dosage: Drug Dosage
More informationManagement of autoimmune hepatitis. Pierre-Emmanuel RAUTOU Inserm U970, Paris Service d hépatologie, Hôpital Beaujon, Clichy, France
Management of autoimmune hepatitis Pierre-Emmanuel RAUTOU Inserm U970, PARCC@HEGP, Paris Service d hépatologie, Hôpital Beaujon, Clichy, France 41 year-old woman, coming to emergency department for fatigue
More informationMyocarditis. Dr. Lewis Au Clinical Research Fellow (melanoma) Royal Marsden Hospital
Myocarditis Dr. Lewis Au Clinical Research Fellow (melanoma) Royal Marsden Hospital Mrs JR (1) 78yo lady Depression on citalopram Otherwise no other active health problems, ECOG 0 Sept 2015: 25mm neurotropic
More informationWilliam M. Lee, MD. Aim: Discuss Clinical Trends in DILI and Acetaminophen Liver Injury
Drug-Induced Liver Injury (DILI) including Acetaminophen (APAP) 2014: Practical Tips William M. Lee, MD Clinical Professor Department of Internal Medicine Division of Gastroenterology, Hepatology & Nutrition
More informationATEZOLIZUMAB (TECENTRIQ )
DRUG ADMINISTRATION SCHEDULE Day Drug Daily Dose Route Diluent Rate Day 1 Atezolizumab 1200 mg IV Infusion 250mL 0.9% Sodium Chloride Over 60 minutes* *The initial dose of atezolizumab must be administered
More informationAim: Discuss Clinical Trends in DILI and Acetaminophen Liver Injury
Drug-Induced Liver Injury (DILI) including Acetaminophen (APAP) 2014: Practical Tips DILI 2014: Aims/Topics Aim: Discuss Clinical Trends in DILI and Acetaminophen Liver Injury William M. Lee, MD Clinical
More informationHOW TO DEAL WITH THOSE ABNORMAL LIVER ENZYMES David C. Twedt DVM, DACVIM Colorado State University Fort Collins, CO
HOW TO DEAL WITH THOSE ABNORMAL LIVER ENZYMES David C. Twedt DVM, DACVIM Colorado State University Fort Collins, CO The identification of abnormal liver enzymes usually indicates liver damage but rarely
More informationAxitinib (renal) Note: in some patients it may be appropriate to increase the dose to 6mg BD before increasing to 7mg BD.
Axitinib (renal) Indication Treatment of advanced renal cell carcinoma after failure of treatment with a first-line tyrosine kinase inhibitor (UK licensed indication states sunitinib) or a cytokine. (NICE
More informationAcute Liver Failure. Agenda. Natalie H Bzowej, MD, PhD, FRCPC. Case Introduction Definition Diagnosis Initial Laboratory Evaluation Acetaminophen NAC
Acute Liver Failure Natalie H Bzowej, MD, PhD, FRCPC Agenda Case Introduction Definition Diagnosis Initial Laboratory Evaluation Acetaminophen NAC 1 Case 27 year old female presents to ER with N/V Denies
More informationVandetanib. ICD-10 codes Codes with a pre-fix C73.
Vandetanib Indication First line treatment of histologically confirmed, unresectable, locally advanced or metastatic medullary thyroid cancer in patients with progressive and symptomatic disease. ICD-10
More informationDrug Induced Liver Injury at a Tertiary Hospital in India: Etiology, Clinical Features and Predictors of Mortality
442 ORIGINAL ARTICLE May-June, Vol. 16 No. 3, 2017: 442-450 The Official Journal of the Mexican Association of Hepatology, the Latin-American Association for Study of the Liver and the Canadian Association
More informationDIABETES AND LABORATORY TESTS. Author: Josephine Davis
DIABETES AND LABORATORY TESTS Author: Josephine Davis LAB TESTS Think twice before you test. What is the reason for testing? Laboratory tests are generally requested in primary care for one of the following
More informationpatient group direction
ACICLOVIR v01 1/8 ACICLOVIR PGD Details Version 1.0 Legal category Staff grades Approved by POM Paramedic (Non-ECP) Nurse (Non-ECP) Emergency Care Practitioner (Paramedic) Emergency Care Practitioner (Nurse)
More informationDocetaxel + Nintedanib
Docetaxel + Nintedanib Available for Routine Use in Burton in-patient Derby in-patient Burton day-case Derby day-case Burton community Derby community Burton out-patient Derby out-patient Indication Second
More informationCisplatin and Gemcitabine Bladder Cancer: Full and split dose
Systemic Anti Cancer Treatment Protocol Cisplatin and Gemcitabine Bladder Cancer: Full and split dose PROCTOCOL REF: MPHAUROCIG (Version No: 1.0) Approved for use in: Neoadjuvant and palliative indications
More informationPazopanib (Continuous vs Drug-free Interval Strategy) STAR Trial
Pazopanib (Continuous vs Drug-free Interval Strategy) STAR Trial A Randomised Multi-Stage Phase II/III Trial of Standard first-line therapy (sunitinib or pazopanib) Comparing Temporary Cessation with Allowing
More informationCiclosporin 25mg, 50mg, 100mg capsules Ciclosporin oral solution 100mg/ml
Shared Care Protocol Ciclosporin for the treatment of rheumatoid arthritis Name of drug, form and strength Background Ciclosporin 25mg, 50mg, 100mg capsules Ciclosporin oral solution 100mg/ml Ciclosporin
More informationPaclitaxel Gastric Cancer
Systemic Anti Cancer Treatment Handbook Paclitaxel Gastric Cancer PROTOCOL REF: MPHAUGIPAC (Version No: 1.0) Approved for use in: Second line treatment of locally advanced and metastatic gastric / gastro-oesophageal
More information